News Archive

Oct 2021

Oct 18, 2021 Nanotechnology Offers New Ways To Fight An Endless Pandemic

Oct 14, 2021 Nanotechnology offers alternative ways to fight COVID-19 pandemic with antivirals

Oct 08, 2021 VIRALEZE™ launch in ADMENTA Italia Group pharmacies in Italy (ASX Announcement)

Oct 01, 2021 2021 Annual General Meeting (ASX Announcement)

Sep 2021

Sep 15, 2021 US patent issued for DEP® cabazitaxel nanoparticle (ASX Announcement)

Aug 2021

Aug 26, 2021 Starpharma annual report and full year financial results (ASX Announcement)

Aug 23, 2021 VIRALEZE™ Protects Against SARS-CoV-2 in Challenge Model (ASX Announcement)

Aug 17, 2021 VIRALEZE™ well tolerated in multiple dose clinical study (ASX Announcement)

Jul 2021

Jul 30, 2021 Quarterly Cashflow and Activities Report (ASX Announcement)

Jul 28, 2021 Lynda Cheng appointed as non-executive director (ASX Announcement)

Jul 27, 2021 Starpharma to present DEP® platform at CRS Annual Meeting (ASX Announcement)

Jul 27, 2021 Starpharma (ASX:SPL) shows 99.99pc antiviral activity against Delta COVID-19 variant

Jul 27, 2021 VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant (ASX Announcement)

Jul 05, 2021 TGA infringement notices for alleged advertising (ASX Announcement)

Jun 2021

Jun 24, 2021 Starpharma to present at Virtual Life Sciences Investor Forum (ASX Announcement)

Jun 21, 2021 VIRALEZE UK update (ASX Announcement)

Jun 19, 2021 COVID-19: Viraleze Nasal Spray Highly Effective Against Alpha, Beta And Gamma Variants

Jun 18, 2021 Latest Testing Confirms Viraleze Highly Effective Against Alpha, Beta and Gamma COVID Variants

Jun 18, 2021 Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

Jun 18, 2021 Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

Jun 18, 2021 Starpharma (ASX:SPL) shows 99.9pc antiviral activity against three COVID-19 variants

Jun 18, 2021 VIRALEZE SPL7013 virucidal against multiple COVID variants (ASX Announcement)

Jun 11, 2021 VIRALEZE antiviral nasal spray registered for sale in India (ASX Announcement)

Jun 01, 2021 Scripps Research Institute testing shows Viraleze highly active against UK COVID strain

Jun 01, 2021 Starpharma (ASX:SPL)'s nasal spray achieves 98% efficacy against COVID-19

Jun 01, 2021 Starpharma (ASX:SPL) shows 98pc antiviral activity against U.K COVID-19 variant

Jun 01, 2021 VIRALEZE SPL7013 highly active in UK variant of coronavirus (ASX Announcement)

May 2021

May 22, 2021 Tackling Covid: How the Harlequins are defending themselves

May 18, 2021 Tax incentives to encourage innovation

May 11, 2021 Harlequins Partners with Anti-Viral Nasal Spray Viraleze

May 11, 2021 Harlequins Partners Antiviral Nasal Spray Brand Viraleze

May 11, 2021 VIRALEZE™ partners with Harlequins in the UK (ASX Announcement)

May 06, 2021 Starpharma (ASX:SPL) launches antiviral nasal spray in Europe

May 06, 2021 VIRALEZE™ launches in Europe (ASX Announcement)

May 04, 2021 Australian company develops a $27 anti-viral nasal spray that 'deactivates' Covid - and it's being used right across the UK

Apr 2021

Apr 28, 2021 Starpharma (ASX:SPL) spends March quarter developing VIRALEZE

Apr 28, 2021 Shareholder Update April 2021

Apr 27, 2021 Quarterly Cashflow and Activities Report

Apr 16, 2021 GlaxoSmithKline hoping to deliver Australia’s next COVID treatment

Apr 11, 2021 Aussie virus killer not to be sneezed at

Mar 2021

Mar 30, 2021 LloydsPharmacy launches nasal spray designed to fight coronavirus

Mar 30, 2021 Covid antiviral nasal spray available from Lloyds

Mar 30, 2021 Lloyds Pharmacy offering first-ever Covid nasal spray Viraleze that 'blocks 99.9% of germs'

Mar 30, 2021 VIRALEZE™ now launched by LloydsPharmacy in the UK

Mar 29, 2021 VIRALEZE™ featured on Sky News

Mar 25, 2021 Starpharma to launch anti-COVID nasal spray with major UK pharmacy chain

Mar 25, 2021 Aussie biotech Starpharma signs deal to sell COVID nose spray in Britain

Mar 25, 2021 VIRALEZE™ to be launched with LloydsPharmacy in the UK

Mar 16, 2021 Starpharma (ASX:SPL) reports DEP HER2-lutetium shows potent anticancer effect

Mar 16, 2021 Starpharma (ASX:SPL) shares rise on breast cancer development

Mar 16, 2021 DEP® HER2-lutetium outperforms in human breast cancer model

Mar 03, 2021 SPL7013 active against other pandemic coronaviruses

Feb 2021

Feb 25, 2021 Starpharma Up With News, Down With None; Timing Entry Makes Sense

Feb 25, 2021 Interim Report and Half-Year Financial Results

Feb 23, 2021 Channel 7 News reports Starpharma's VIRALEZE has been registered in the UK/Europe

Feb 23, 2021 VIRALEZE™ antiviral nasal spray registered in Europe

Feb 12, 2021 Starpharma signs research agreement with MSD

Feb 12, 2021 Starpharma signs DEP® ADC Research Agreement with MSD

Feb 10, 2021 Ausbiz interviews Starpharma CEO Dr Jackie Fairley

Feb 09, 2021 AZD0466 clinical DEP® program global expansion

Feb 04, 2021 Aussie condom antiviral recruited for Covid-19 fight

Feb 04, 2021 Australian-developed COVID nasal spray set to land in Europe

Feb 03, 2021 Channel 7 evening news features Starpharma's VIRALEZE

Feb 02, 2021 Starpharma prepares to launch COVID-killing nasal spray

Jan 2021

Jan 29, 2021 Quarterly Cashflow and Activity Report

Jan 09, 2021 Leading broker names the ASX healthcare shares to buy in 2021